Researchers in University of Cambridge and other institutions recently reported that they developed a new drug on mixed lineage leukemia treatment , animal experiments and in vitro experiments on human cells have shown that the drug effectively.

Mixed lineage leukemia gene MLL by the code for the mutation caused the gene mutation will guide the production of a "fusion protein", this protein to influence other genes will eventually lead to leukemia. In this chain disease, the researchers found that an intervention session, that requires a code for the fusion protein of protein to help BET can affect other genes.

In the UK "Nature" magazine Web site, British researchers reported that they found a BET protein function can block chemicals. Experiments show, called I-BET151 substance effective in the treatment of hybrid mice suffering from leukemia, cultured in vitro for human disease cells also have a therapeutic effect.

Brian Huntley said that mixed lineage leukemia difficult to treat, patients often need bone marrow transplant to live, hope that the results of this study will help patients get rid of the dependence of bone marrow transplantation.